8月24日，药明合联盘中下跌3.28%，报69.3港元/股，成交额7164.51万港元。公司今日召开董事会审议中期业绩并发布中报，适逢所属生命科学工具和服务板块整体走弱，同业金斯瑞生物科技跌4.06%、药明生物跌2.75%、药明康德跌2.33%，板块联动下行压力明显。此前公司股价受新加坡基地BCM3产线GMP放行及中报预期等多重利好推动连续走高，短期存在获利回吐需求。
药明合联是全球领先的ADC及生物偶联药物CRDMO企业，主要从事抗体偶联药物的发现、工艺开发及GMP生产服务，业务覆盖国内、北美、欧洲及全球其他市场。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.